(Information sent by the signatory company)

– SNZ 1969® probiotic strain helps effectively control symptoms of IBS-D and IBS-C, latest clinical study shows

HYDERABAD, India, Nov. 29, 2022 /PRNewswire/ — Latest study shows that Bacillus coagulans SNZ 1969® (Weizmannia coagulans SNZ 1969) from Sanzyme Biologics, a spore-forming natural probiotic strain, with more than five decades of use and More than 30 human studies in all age groups have shown its efficacy in treating IBS symptoms. This study is unique in that it encompasses the IBS-Diarrhea and IBS-Constipation groups with a larger number of subjects.

Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction, estimated to affect around 11% of people worldwide. The result of this study will be important to supplement manufacturers as it may help design products that address consumers’ need to manage IBS symptoms with a scientifically studied probiotic strain. Several factors, such as the growing fear of antibiotic resistance, increased consumer demand for natural drug substitutes, and the emergence of scientific and clinical evidence demonstrating the efficacy of probiotics, have contributed to many health professionals health consider probiotics as an alternative to pharmacological remedies.

In a randomized, double-blind, placebo-controlled study, the probiotic potential of SNZ 1969® has been studied in subjects with constipation-predominant irritable bowel syndrome (IBS-C) and diarrhea-predominant (IBS-D). A significant reduction in the GSRS IBS score was observed in both treatment groups compared to placebo (P < 0.0001). SNZ 1969® was well tolerated and showed significant relief of IBS-associated clinical symptoms compared with placebo and improved quality of life in IBS patients.

This study was carried out at the Apollo Hospitals in Hyderabad (India) and was published in the International Journal of Basic

The same strain has previously been studied for gastrointestinal upset, intestinal motility, and intermittent constipation among healthy subjects. The study on gastrointestinal complaints showed an improvement in SODA total scores, including specific symptoms such as belching, bloating, heartburn, passing gas, nausea, bad breath, and sour taste compared to placebo. The study on intestinal motility concluded that SNZ 1969® reaches the colon intact and improves intestinal motility and the composition of the intestinal microbiota.

Sanzyme Biologics was incorporated in 1969 as Uni-Sankyo. Over the past five decades, Sanzyme Biologics has built its strength in the field of probiotics by developing scientifically studied and well-documented probiotic strains, and has pioneered their applications beyond human health, in the sectors aquatic, veterinary, poultry and bioremediation. Sanzyme Biologics is present on the market in more than 40 countries.

To learn more, visit https://www.sanzymebiologics.com/ or contact info@sanzymebiologics.com. Phone: 91-40-48589999

Photo: https://mma.prnewswire.com/media/1956162…Logo: https://mma.prnewswire.com/media/1956163…

View original content: https://www.prnewswire.com/news-releases/la-cepa-probiotica-snz-1969-ayuda-a-controlar-eficazmente-los-sintomas-del-sii-d-y-el-sii-e-301689035.html